Last reviewed · How we verify
QLH12016
At a glance
| Generic name | QLH12016 |
|---|---|
| Sponsor | Qilu Pharmaceutical Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Clinical Study of QLC5508 and/or QLH12016 in Combination With Other Anti-tumor Therapies in Subjects With Advanced Prostate Cancer (PHASE1, PHASE2)
- Study of QLH12016 in Combination With Novel Hormonal Agent in Subjects With Advanced Prostate Cancer (PHASE1, PHASE2)
- Trial of QLH12016 in Patients With Metastatic Castration Resistant Prostate Cancer (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- QLH12016 CI brief — competitive landscape report
- QLH12016 updates RSS · CI watch RSS
- Qilu Pharmaceutical Co., Ltd. portfolio CI